WuXi AppTec Signs Definitive Agreement to Sell WuXi Advanced Therapies to Altaris, LLC

Philadelphia and Shanghai, 24 December 2024 - WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, announced that it has entered into a definitive agreement to sell the US and UK based operations of WuXi Advanced Therapies (ATU), its cell and gene therapy unit, to Altaris, LLC, a healthcare investment firm headquartered in New York.

All other WuXi AppTec operations remain unchanged, and WuXi AppTec's major business units - WuXi Chemistry, WuXi Biology and WuXi Testing - will continue our sharp focus on supporting innovative partners globally through the unique CRDMO enabling platform.

The transaction is expected to close in the first half of 2025, subject to customary closing conditions and receipt of required regulatory approvals.

Edward Hu, CEO of WuXi ATU, said, "Today's agreement is a positive step forward for the vital services that ATU provides. Altaris is committed to growing the ATU businesses by supporting its employees, customers and patients. At the same time, WuXi AppTec will remain laser-focused on our 'follow-the-customer' and 'follow-the-molecule' strategies, as we continue to move toward our vision that 'every drug can be made and every disease can be treated.'"

Advisors
J.P. Morgan served as financial advisor, and Wilson Sonsini Goodrich & Rosati acted as legal advisor, to WuXi AppTec. Kirkland & Ellis LLP acted as legal counsel for Altaris.

About WuXi Advanced Therapies
As the advanced therapies business unit of WuXi AppTec, WuXi Advanced Therapies is a Contract Testing, Development and Manufacturing Organization (CTDMO) that offers advanced platforms and end-to-end solutions that enable the discovery, development, testing, manufacturing, and commercialization of cell and gene therapies. Our services and solutions accelerate time to market and support customer programs around the world. For more information visit www.advancedtherapies.com .

About WuXi AppTec
As a global company with operations across Asia, Europe, and North America, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable the global pharmaceutical and life sciences industry to advance discoveries and deliver groundbreaking treatments to patients. Through its unique business models, WuXi AppTec's integrated, end-to-end services include chemistry drug CRDMO (Contract Research, Development, and Manufacturing Organization), biology discovery, preclinical testing and clinical research services, advanced therapies CTDMO (Contract Testing, Development and Manufacturing Organization), helping customers improve the productivity of advancing healthcare products through cost-effective and efficient solutions. WuXi AppTec received an AA ESG rating from MSCI for the fourth consecutive year in 2024, and its open-access platform is enabling more than 6,000 customers from over 30 countries to improve the health of those in need - and to realize the vision that "every drug can be made and every disease can be treated."

About Altaris, LLC
Altaris is an investment firm with an exclusive focus on acquiring and building companies in the healthcare industry. Since its inception in 2003, Altaris has invested in more than 50 companies across a range of healthcare subsectors, with a consistent goal of delivering value to the healthcare system and generating attractive financial returns for investors. Altaris is headquartered in New York City and manages $10 billion of equity capital. For more information, please visit www.altariscap.com .